Mallen, A. R., Filiaci, V. L., Levine, D. A., Thiel, K., Aghajanian, C. A., Meng, X., … Leslie, K. K. (2018). Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. In Gynecologic Oncology (Vol. 149, pp. 29–30). Elsevier BV. https://doi.org/10.1016/j.ygyno.2018.04.069

Mallen, A. R., V. L. Filiaci, D. A. Levine, K. Thiel, C. A. Aghajanian, X. Meng, E. Devor, et al. “Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers.” In Gynecologic Oncology, 149:29–30. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.069.

Mallen AR, Filiaci VL, Levine DA, Thiel K, Aghajanian CA, Meng X, et al. Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. In: Gynecologic Oncology. Elsevier BV; 2018. p. 29–30.

Mallen, A. R., et al. “Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers.” Gynecologic Oncology, vol. 149, Elsevier BV, 2018, pp. 29–30. Crossref, doi:10.1016/j.ygyno.2018.04.069.

Mallen AR, Filiaci VL, Levine DA, Thiel K, Aghajanian CA, Meng X, Devor E, Moore KN, Powell MA, Secord AA, Tewari KS, Bender DP, Stuckey AR, Fowler JM, Dewdney SB, Leslie KK. Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. Gynecologic Oncology. Elsevier BV; 2018. p. 29–30.